Heated intraperitoneal chemotherapy (HIPEC) use for ovarian cancer in the United States increases after publication of clinical trial and is associated with higher short-term cost and morbidity

Abstract

Objective: The goals of this study were (1) to determine whether trends in use of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer treatment increased after “HIPEC in Ovarian Cancer” was published in January 2018, and (2) to compare associated rates of hospital-based outcomes, including length of stay, intensive care unit (ICU) admission, complications, and costs, in ovarian cancer patients who underwent surgery with or without HIPEC.